De-escalation of therapy in a patient with chronic obstructive pulmonary disease: A clinical observation

Current clinical guidelines for chronic obstructive pulmonary disease assign a significant role to the combination of a long-acting muscarinic antagonist / a long-acting β2-agonist (LAMA / LABA). The combined use of LAMA / LABA improves symptoms, quality of life, reduces the frequency of exacerbations, hospitalizations and mortality. Despite the existence of various guide-lines for the pharmacological treatment of COPD, there is a significant discrepancy between the recommendations and the actual practice of prescribing inhaled corticosteroids (ICS), especially in low-risk groups, where triple therapy is often overly prescribed. The purpose of this clinical observation is to demonstrate the de-escalation of triple therapy (ICS / LAMA / LABA) to a dual bronchodilation (LAMA / LABA) in a patient with COPD. Based on the dynamics of clinical, instrumental and laboratory parameters of the patient, the absence of indications for the appointment of ICS has been proven. The appointment of combined double therapy indacaterol / glycopyrronium bromide 110/50 mcg inhalation 1 time/day is justified. The positive effect dual bronchodilation therapy (indacatero / glycopyrronium bromide) has been demonstrated the symptoms and quality of life of the patient. The absence of adverse events against the background of taking indacaterol / glycopyrronium bromide and the convenience of using the Breezhaler® inhaler were established. Based on the above, conclusions are drawn: a thorough assessment of the indications for the appointment of ICS in stable patients with chronic obstructive pulmonary disease is necessary; the use of a combination of indacaterol / glycopyrronium bromide in one device 1 time per day provides better adherence to treatment; the inhaler Breezhaler® ensures optimal delivery of a dose of the drug to the lungs.

1. Cunha AS, Raposo B, Dias F, Henriques S, Martinho H, Pedro AR. Management of Chronic Obstructive Pulmonary Disease: Constraints in Patient Pathway and Mitigation Strategies. Port J Public Health. 2024;12:1-8. https://doi.org/10.1159/000535474.

2. Samorodskaya IV, Bolotova EV, Dudnikova AV. The dynamic and structure of mortality from respiratory diseases and COVID-19 in the Russian Federation for 2019-2021. Clinical Medicine (Russian Journal). 2022;100(11-12):535-539. (In Russ.) https://doi.org/10.30629/0023-2149-2022-100-11-12-535-539.

3. Koopman M, Posthuma R, Vanfleteren LEGW, Simons SO, Franssen FME. Lung Hyperinflation as Treatable Trait in Chronic Obstructive Pulmonary Disease: A Narrative Review. Int J Chron Obstruct Pulmon Dis. 2024;19:1561-1578. https://doi.org/10.2147/COPD.S458324.

4. Cazzola M, Rogliani P, Laitano R, Calzetta L, Matera MG. Beyond Dual bronchodilation - Triple Therapy, When and Why. Int J Chron Obstruct Pulmon Dis. 2022;17:165-180. https://doi.org/10.2147/COPD.S345263.

5. Bolotova EV, Dudnikova AV, Shulzhenko LV. Experience of using a triple fixed combination in the treatment of patients with chronic obstructive pulmonary disease. Terapevticheskii Arkhiv. 2022;94(3):396-400. https://doi.org/10.26442/00403660.2022.03.201406.

6. Авдеев СН, Айсанов ЗР, Ардашева ТВ, Белевский АС, Демко ИВ, Зайцев АА и др. Хроническая обструктивная болезнь легких: клинические рекомендации. 2023 г. Режим доступа: https://spulmo.ru/upload/kr/HOBL_2023_draft.pdf.

7. Malerba M, Foci V, Patrucco F, Pochetti P, Nardin M, Pelaia C, Radaeli A. Single Inhaler LABA/LAMA for COPD. Front Pharmacol. 2019;10:390. https://doi.org/10.3389/fphar.2019.00390.

8. Melani AS, Croce S, Fabbri G, Messina M, Bargagli E. Inhaled Corticosteroids in Subjects with Chronic Obstructive Pulmonary Disease: An Old, Unfinished History. Biomolecules. 2024;14(2):195. https://doi.org/10.3390/biom14020195.

9. Avdeev SN, Leshchenko IV, Aisanov ZR, Arkhipov VV, Belevskiy AS, Ovcharenko SI et al. New clinical guidelines for COPD - a paradigm shift: A review. Terapevticheskii Arkhiv. 2024;96(3):292-297. https://doi.org/10.26442/00403660.2024.03.202646.

10. Banerji D, Fogel R, Patalano F. Indacaterol/glycopyrronium: a dual bron-chodilator for COPD. Drug Discov Today. 2018;23(1):196-203. https://doi.org/10.1016/j.drudis.2017.10.015.

11. Frampton JE. QVA149 (indacaterol/glycopyrronium fixed-dose combination): a review of its use in patients with chronic obstructive pulmonary disease. Drugs. 2014;74(4):465-488. https://doi.org/10.1007/s40265-014-0194-8.

12. Sanders MJ. Guiding Inspiratory Flow: Development of the In-Check DIAL G16, a Tool for Improving Inhaler Technique. Pulm Med. 2017;2017:1495867. https://doi.org/10.1155/2017/1495867.

13. Dolovich MB, Kuttler A, Dimke TJ, Usmani OS. Biophysical model to predict lung delivery from a dual bronchodilator dry-powder inhaler. Int J Pharm X. 2019;1:100018. https://doi.org/10.1016/j.ijpx.2019.100018.